Our work encompasses more than 15 years of scientific discoveries, from preclinical asthma models to translational research to human disease and clinical trials. Our goal is to improve the lives of those suffering from chronic diseases.

Macrophage Therapy  is a new therapeutic approach: we aim to treat patients with asthma with autologous monocyte-derived macrophages in which PLA2G5, a master regulator of inflammation,  has been removed using CRISPR technology.

Our long-term goal is to improve transplantation therapy to cure chronic diseases, including asthma, lung cancer, and COPD.